Literature DB >> 8702576

Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins.

L M Dong1, K H Weisgraber.   

Abstract

Human apolipoprotein (apo) E contains an amino- and a carboxyl-terminal domain, which are connected by a hinge region (approximately residues 165 to 215). The interaction of the two domains has been suggested to be responsible for the apoE4-binding preference for very low density lipoproteins (VLDL). In the absence of this interaction in apoE3, the preference is for high density lipoproteins (HDL). To exclude the possibility that the interaction of apoE with other apolipoproteins on the native particles may contribute to the isoform-specific preferences, VLDL-like emulsion particles were incubated with apoE, and the lipid-bound apoE was separated from free apoE on a Superose 6 column. The apoE4 bound more effectively to these particles than did apoE3, indicating that the apoE4 preference for VLDL is due not to interactions with other apolipoproteins but to an intrinsic property of apoE4, likely related to domain interaction. Previously, arginine 61 was shown to be critical for the isoform preferences, suggesting that it interacted with an acidic residue(s) in the carboxyl terminus. Substitution of arginine 61 with lysine did not alter the preference of apoE4 for VLDL, demonstrating that a positive charge rather than a specific requirement for arginine is critical for domain interaction. To identify the acidic residue(s) in the carboxyl terminus interacting with arginine 61, the six acidic residues (244, 245, 255, 266, 270, and 271) in a region known to be important for both lipoprotein association and isoform-specific preferences were substituted individually with alanine in apoE4. Only substitution of glutamic acid 255 altered the preference of apoE4 from VLDL to HDL, indicating that this was the sole residue in the carboxyl terminus that interacts with arginine 61. The participation of the hinge region in domain interaction was examined with internal deletion mutants. Deletion of the residues 186-202 or 186-223, representing major portions of the hinge region, had no effect on the apoE4 preference for VLDL. This suggests that the hinge region may act as a spacer that connects the two domains. Further deletion into the carboxyl-terminal domain (to residue 244) results in a loss of apoE4 VLDL binding. These studies establish that interaction of arginine 61 and glutamic acid 255 mediates apoE4 domain interaction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702576     DOI: 10.1074/jbc.271.32.19053

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  123 in total

1.  The extent of pyrene excimer fluorescence emission is a reflector of distance and flexibility: analysis of the segment linking the LDL receptor-binding and tetramerization domains of apolipoprotein E3.

Authors:  Gursharan K Bains; Sea H Kim; Eric J Sorin; Vasanthy Narayanaswami
Journal:  Biochemistry       Date:  2012-07-26       Impact factor: 3.162

2.  Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.

Authors:  Y Huang; X Q Liu; T Wyss-Coray; W J Brecht; D A Sanan; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  Acrolein modification impairs key functional features of rat apolipoprotein E: identification of modified sites by mass spectrometry.

Authors:  Tuyen N Tran; Malathi G Kosaraju; Shiori Tamamizu-Kato; Olayemi Akintunde; Ying Zheng; John K Bielicki; Kent Pinkerton; Koji Uchida; Yuan Yu Lee; Vasanthy Narayanaswami
Journal:  Biochemistry       Date:  2014-01-08       Impact factor: 3.162

4.  Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction.

Authors:  Samuel O Adeosun; Xu Hou; Baoying Zheng; Craig Stockmeier; Xiaoming Ou; Ian Paul; Thomas Mosley; Karl Weisgraber; Jun Ming Wang
Journal:  J Biol Chem       Date:  2013-12-09       Impact factor: 5.157

5.  Interaction between the N- and C-terminal domains modulates the stability and lipid binding of apolipoprotein A-I.

Authors:  Mao Koyama; Masafumi Tanaka; Padmaja Dhanasekaran; Sissel Lund-Katz; Michael C Phillips; Hiroyuki Saito
Journal:  Biochemistry       Date:  2009-03-24       Impact factor: 3.162

6.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

7.  Role of Apolipoprotein E in β-Amyloidogenesis: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO FIBRIL CONVERSION OF Aβ IN VITRO AND BRAIN Aβ DEPOSITION IN VIVO.

Authors:  Yukiko Hori; Tadafumi Hashimoto; Hidetoshi Nomoto; Bradley T Hyman; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

8.  Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia.

Authors:  Irina N Gorshkova; Kyriakos E Kypreos; Donald L Gantz; Vassilis I Zannis; David Atkinson
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

9.  Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles.

Authors:  Dimitra Georgiadou; Angeliki Chroni; Konstantinos Drosatos; Kyriakos E Kypreos; Vassilis I Zannis; Efstratios Stratikos
Journal:  Atherosclerosis       Date:  2012-11-23       Impact factor: 5.162

10.  Sex-specific interaction between APOE genotype and carbohydrate intake affects plasma HDL-C levels: the Strong Heart Family Study.

Authors:  M J Mosher; L A Lange; B V Howard; E T Lee; L G Best; R R Fabsitz; J W Maccluer; K E North
Journal:  Genes Nutr       Date:  2008-03-29       Impact factor: 5.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.